Capella NURS FPX 4015 Assessment 5

Capella NURS FPX 4015 Assessment 5

Name

Capella University

NURS-FPX4015 Pathophysiology, Pharmacology, and Physical Assessment: A Holistic Approach to Patient-Centered Care

Prof. Name

Date

Comprehensive Head-To-Toe Assessment

Hello, Mr. Evan Wright. My name is ________. I will perform a complete head-to-toe evaluation with you today. The goal is to gain an understanding of your health, considering your history of type 2 Diabetes Mellitus (DM) with diabetic peripheral neuropathy. This enables us to develop a care plan personalized to your specific needs. If anything during the exam feels uncomfortable or overwhelming, please do not hesitate to let me know. Let’s go ahead and get started.

Systematic and Precise Evaluation

As I begin the assessment, “Mr. Wright, you seem a little tired today. How are you feeling?” “Let’s check your vital signs to get a clearer picture.” “Your blood pressure is a bit elevated. That can sometimes happen with diabetes or vascular issues. Have you been feeling more stressed or unwell lately?” “I am going to check the pulses in your feet now, first on top, then behind the ankles.” “These pulses are quite faint, which suggests reduced circulation in your lower legs.” “Now I am going to take a closer look at your legs and feet. Please let me know if anything feels uncomfortable.” “The skin here looks shiny and a little discolored.

I see some swelling and hair loss, which can be signs of peripheral arterial disease, which occurs with diabetes.” “It is good that there are no wounds or ulcers right now, but since you have lost some sensation in your feet, we will need to keep a close watch.” “Are you having any numbness or tingling in your feet?” “I will check your sensation now using light touch and a monofilament to see how well you can feel pressure in different areas.” “It looks like the sensation is reduced, which is common in diabetic peripheral neuropathy.” “Now I will check your ankle reflexes.” “These reflexes are a little weak, which fits with nerve changes that can happen with diabetes.”

Capella NURS FPX 4015 Assessment 5

“As I listen to your heart now, I want you to know it sounds nice and clear, no murmurs or irregular rhythms, which is great,” I say reassuringly. “But I do want to remind you that the pulses in your feet are still faint, which points to reduced blood flow down there. Have you noticed any changes like cold feet or pain when walking?” I then move on to the next part. “Let me listen to your lungs now,” I say, placing my stethoscope gently. After a moment, I mention, “Your breathing sounds clear, no wheezing, crackles, or anything concerning. Have you been having any shortness of breath or coughing lately?” “Now I’m going to check your stomach area, alright?” I explain. “Let me know if you feel any discomfort as I press around.

” As I listen and palpate, I say, “Everything sounds normal, and I don’t feel any swelling or tenderness. Any recent issues with digestion or appetite?” Finally, I shift to mobility. “Can you move your arms and legs for me, please?” I observe as you follow along. “Any pain, tightness, or difficulty while doing that?” I add, “You mentioned having muscle cramps in your lower legs earlier, how is that happening? It might be linked to the reduced circulation we talked about.” “I will make sure we address that in your care plan,” I say. “And please let me know if anything ever feels off we will work through it together.”

Analysis of Diagnosis and Findings

Mr. Wright, I appreciate your participation in today’s examination. I would like to discuss findings openly with you so we can work together on a plan. Upon review of your current health status, two prominent concerns have emerged: insufficient management of type 2 diabetes and clinical indicators suggestive of Peripheral Vascular Disease (PVD). Your report of not adhering to prescribed antidiabetic medications over the past eight months is a factor contributing to sustained hyperglycemia. This led to progressive systemic damage. One of the most concerning outcomes observed is diminished sensation in both feet. This sensory loss aligns with diabetic peripheral neuropathy. It is a serious risk of prolonged, uncontrolled blood glucose levels.

This condition affects the peripheral nerves in the lower extremities, impairing your ability to detect injuries and pressure-related wounds. This increases the risk of infection (Gebabo et al., 2021). Further findings during the peripheral vascular assessment included weak pedal pulses, subtle skin discoloration, dryness, and mild swelling. These signs are associated with impaired arterial circulation. These indications are characteristic of PVD, a condition where narrowed blood vessels limit oxygenated blood flow to the extremities (Das et al., 2022). Addressing both the metabolic and vascular aspects of your condition will be central to your care plan moving forward.

Capella NURS FPX 4015 Assessment 5

When type 2 diabetes and PVD occur together, they increase the chance of complications such as delayed tissue repair, localized infections, and the potential for chronic ulcers in the lower extremities. Despite these risks, it is essential to emphasize that consistent and targeted interventions reduce the onset and severity of such complications. Priority actions will include reinitiating your antidiabetic regimen and performing routine self-examinations of your feet to detect early signs of skin breakdown.

This also includes wearing protective footwear to minimize pressure and trauma, and maintaining regular follow-up with your care team (American Diabetes Association, 2025). Moreover, to address factors that influence your ability to adhere to treatment, we aim to connect you with community-based resources that offer support in areas such as housing, nutrition, and access to care. A coordinated, multidisciplinary approach will support your physical health and quality of life. I want you to know that I will be here to help you throughout this journey, every step of the way.

Pharmacological Needs

I would like to share the core focus of your treatment with you, so we can work together to manage your health more effectively. The cornerstone of Mr. Evan Wright’s treatment plan lies in achieving and maintaining adequate glycemic control, as sustained elevations in blood glucose are contributing to both his vascular insufficiency and nerve dysfunction. In the setting of type 2 DM, constant hyperglycemia initiates a cascade of metabolic disturbances that compromise blood vessel integrity and impair neural conduction. This accelerates conditions such as peripheral arterial disease and diabetic neuropathy.

Metformin is the first-line pharmacologic agent due to its insulin-sensitizing properties and satisfactory safety profile. Where extra cardiovascular and renal protection is indicated, agents such as SGLT2 inhibitors and GLP-1 receptor agonists are integrated into the regimen to broaden therapeutic benefit (Palmer et al., 2021). The prevention of complications, such as ulcer formation, delayed wound healing, and potential limb ischemia, depends on blood glucose regulation and adequate vascular support. This includes the possible use of low-dose aspirin for its antiplatelet effects and statins for lipid control and plaque stabilization. For the characteristic release of peripheral exertional discomfort, a manifestation of peripheral arterial disease, cilostazol is prescribed to enhance peripheral circulation through vasodilatory and antithrombotic mechanisms.

Capella NURS FPX 4015 Assessment 5

The approach to addressing Mr. Wright’s neuropathic signs should include consideration of pharmacological agents such as gabapentin and duloxetine. These agents reduce nerve pain and improve functional status. These medications can contribute to his comfort and ability to perform daily activities. However, any pharmacotherapy must be initiated with an awareness of the potential adverse effects. Gabapentinoids and serotonin-norepinephrine reuptake inhibitors cause sedation, dizziness, and impaired coordination in older adults (Bernatoniene et al., 2023).

Antiplatelet agents like aspirin pose an increased bleeding risk, while cilostazol, a vasodilator, has been associated with side effects such as palpitations and headaches. Mr. Wright would benefit from a personalized medication care plan that prioritizes efficacy and safety. Regular follow-up visits will be essential to evaluate his response to treatment, monitor for potential side effects, and make timely changes as needed to maintain therapeutic balance and decrease the hazard of polypharmacy-related problems (Bernatoniene et al., 2023). I will make it a priority to reassess your medications regularly so you feel supported and safe throughout your treatment.

Pathophysiology of the Disease Process

Mr. Wright, I would like to walk you through how your conditions are affecting your body so we can work together to manage them. Mr. Wright, gaining insight into the underlying effects of your health conditions is essential in managing them. Type 2 diabetes leads to hyperglycemia. This, over time, compromises the function of both your circulatory and nervous systems. One of the early signs of nerve involvement is peripheral neuropathy. It is characterized by tingling, numbness, or burning sensations in the feet. This results from impaired nerve signaling. Moreover, diabetes impairs the body’s ability to heal wounds in the lower extremities, increasing the chance of infections (Baum et al., 2021). PVD reduces blood flow by narrowing arteries in the legs.

This can cause discomfort during movement and delay tissue repair. When these two conditions coexist, the risk of complications, such as foot ulcers, infections, and delayed wound healing, increases noticeably. It becomes crucial to maintain stable blood glucose levels, encourage healthy circulation, and perform daily foot inspections (Baum et al., 2021). If you observe persistent leg pain, non-healing wounds, and noticeable changes in your skin’s color or temperature, please report these symptoms promptly. Our collaborative care approach will focus on optimizing your medications, lifestyle choices, and routine monitoring to reduce risks and support your long-term well-being.

Capella NURS FPX 4015 Assessment 5

Type 2 diabetes and PVD impact the body by damaging blood vessels and nerves in the lower limbs. This can manifest as burning, tingling, numbness, or sharp pain in the feet, known as peripheral neuropathy. Patients experience cramping and aching in the legs during movement, called intermittent claudication, due to reduced blood flow. Visually, the feet and legs appear pale, shiny and discolored, with slow-healing wounds around the toes or heels. These wounds are painless due to nerve damage.

This can delay detection and treatment. Patients describe their symptoms as “pins and needles,” “burning feet,” or leg pain when walking (Baum et al., 2021). These symptoms reflect how the disease process disrupts circulation and nerve signaling. It increases the risk of infection, delayed healing, and serious complications like foot ulcers and amputation if not properly managed. I encourage you to reach out to me if you notice any of these signs so I can act quickly and prevent further problems.

Critical Thinking and Decision Making

I would like to walk you through a complete care plan that puts your long-term health and comfort at the center of everything we do. The management of your condition requires a full approach that prioritizes blood glucose regulation to prevent vascular and neurological deterioration. Individuals with a disease of type 2 DM, peripheral neuropathy, and PVD are at heightened risk for complications such as chronic wounds, infections, and delayed healing (Fan et al., 2025). The first step in this process involves reassessing your current diabetic treatment regimen, your use of metformin, and determining if additional pharmacological agents are necessary to enhance glycemic control. Daily monitoring of blood sugar levels, along with heightened awareness of symptoms such as numbness, tingling, or slow-healing lesions, will enable early changes in care to support long-term health outcomes.

Effective management of type 2 DM with peripheral neuropathy and PVD requires a complete approach built on three key priorities. This includes achieving glycemic control, preventing vascular complications, and promoting patient self-care. The American Diabetes Association (ADA) endorses upholding an HbA1c level of <7% for most non-pregnant adults to prevent microvascular damage, supporting the priority of optimizing blood glucose through appropriate use of medications such as metformin, GLP-1 receptor agonists, or SGLT2 inhibitors (American Diabetes Association, 2023). In addition, the Centers for Disease Control and Prevention (CDC) emphasize that consistent exercise is among the most powerful methods to enhance well-being.

Capella NURS FPX 4015 Assessment 5

Individuals are advised to complete at least 2.5 hours of moderately challenging cardio workouts weekly, which can be broken down into 30-minute sessions over five days. They include resistance training on two or more days each week to enhance muscle function and support metabolic balance (CDC, 2023). These guideline-supported strategies empower patients to reduce complications, preserve limb function and sustain long-term health.The management of peripheral vascular complications requires a comprehensive approach focused on enhancing limb perfusion and preventing disease progression. Pharmacologic therapy includes agents such as cilostazol. It reduces symptoms like exercise-induced leg discomfort by improving arterial blood flow. Antiplatelet therapy (e.g., low-dose aspirin) and lipid-lowering medications, such as statins, are vital for minimizing vascular inflammation and reducing the risk of atherosclerotic events (Musial et al., 2024).

Beyond medication, behavioral modifications are integral to achieving long-term vascular health. Eliminating tobacco use, adopting a nutrient-rich diet, and engaging in structured physical activity improve circulatory efficiency. Routine inspection of the feet should become part of daily care to identify any early indicators of tissue compromise quickly. Enhancing patient education about the interconnected nature of these interventions will empower patients to participate in managing their disease (Liu et al., 2025). Our objective is to implement preventive strategies that preserve mobility, reduce complications, and promote sustained health outcomes. I am committed to supporting you every step of the way as I work to maintain your mobility and protect your health.

Conclusion

The comprehensive head-to-toe assessment of Mr. Evan Wright highlights the urgent need for coordinated care to manage his DM, peripheral neuropathy and PVD. Clinical findings underscore the importance of restoring glycemic control, enhancing peripheral circulation, and implementing preventive measures to mitigate the risk of complications. Pharmacologic therapies, lifestyle interventions, and patient education must be integrated into a personalized care plan tailored to his current health status and socioeconomic challenges.

References

American Diabetes Association. (2023). Understanding A1C. https://diabetes.org/about-diabetes/a1c

American Diabetes Association. (2025). Understanding neuropathy and your diabetes. https://diabetes.org/about-diabetes/complications/neuropathy

Baum, P., Toyka, K. V., Blüher, M., Kosacka, J., & Nowicki, M. (2021). Inflammatory mechanisms in the pathophysiology of Diabetic peripheral Neuropathy (DN). New aspects. International Journal of Molecular Sciences, 22(19), 10835. https://doi.org/10.3390/ijms221910835

Bernatoniene, Ščiupokas A, Kopustinskiene, D. M., & Petrikonis K. (2023). Novel drug targets and emerging pharmacotherapies in neuropathic pain. Pharmaceutics, 15(7), 1799–1799. https://doi.org/10.3390/pharmaceutics15071799

Centers for Disease Control and Prevention. (2023). Physical activity for adults: An overview. https://www.cdc.gov/physical-activity-basics/guidelines/adults.html

Das, P., Bhattacharya, D., & Sathpathy, R. (2022). A study of the peripheral vessels in patients with type 2 diabetes mellitus with or without foot involvement. Cureus. https://doi.org/10.7759/cureus.28542

Capella NURS FPX 4015 Assessment 5

Fan, Z., Liu, Y., Xie, H., Yang, Q., Zhang, G., Zhang, P., & Ding, H. (2025). Analysis of risk factors for foot ulcers in diabetes patients with neurovascular complications. BioMed Central Public Health, 25(1). https://doi.org/10.1186/s12889-025-21639-1

Gebabo, T. F., Zewdie, T. H., Shagaro, S. S., & Haile, F. (2021). Determinants of peripheral neuropathy among diabetic patients under follow-up in chronic care clinics of public hospitals at Gamo and Gofa zones, southern Ethiopia. Public Library of Sciences ONE, 16(2). https://doi.org/10.1371/journal.pone.0246722

Liu, S., Ding, H., Li, D., Lu, F., Luo, G., He, Y., Li, H., Zeng, X., Li, K., & Gong, D.-E. (2025). Foot screening and customized health education program for patients with diabetic peripheral neuropathy: A nurse-led, real-world observational study. International Journal of Nursing Studies Advances, 8, 100291. https://doi.org/10.1016/j.ijnsa.2025.100291

Musial, D. C., Ajita, M. E., & Guilherme. (2024). Benefits of Cilostazol’s effect on vascular and neuropathic complications caused by diabetes. Medical Sciences, 13(1), https://doi.org/10.3390/medsci13010001

Palmer, S. C., Tendal, B., Mustafa, R. A., Vandvik, P. O., Li, S., Hao, Q., Tunnicliffe, D., Ruospo, M., Natale, P., Saglimbene, V., Nicolucci, A., Johnson, D. W., Tonelli, M., Rossi, M. C., & Badve, S. V. (2021). Sodium-Glucose Cotransporter Protein-2 (SGLT-2) inhibitors and Glucagon-Like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: Systematic review and network meta-analysis of randomised controlled trials. British Medical Journal, 372. https://doi.org/10.1136/bmj.m4573